ADMA correlates with portal pressure in patients with compensated cirrhosis

European Journal of Clinical Investigation

Volumn 37, Issue 6, 2007, Pages 509-515

  Vizzutti, F ^a   Romanelli, R G ^a   Arena, U ^a   Rega, L ^b   Brogi, M ^a   Calabresi, C ^a   Masini, E ^a   Tarquini, R ^a   Zipoli, M ^a   Boddi, V ^a   Marra, F ^a   Laffi, G ^a   Pinzani, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliero   (Italy)

Author keywords

Endothelial dysfunction; HVPG; Liver cirrhosis; NO; Portal hypertension

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRATE; NITRITE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; HEPATIC VEIN; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; MEASUREMENT; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERY; VENOUS PRESSURE;

ADULT; AGED; ARGININE; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NITRIC OXIDE; PORTAL PRESSURE;

EID: 34249327260     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01814.x     Document Type: Article

References (36)

1. Gupta TK, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Baillieres Clin Gastroenterol 1997 11:203 19.
2. Bosch J, Garcia-Pagan JC. Complication of cirrhosis. I. Portal hypertension. J Hepatol 2000 32:141 56.
3. Bhatal PS, Grossman HJ. Reduction of the increased intrahepatic vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985 1:325 37.
4. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998 114:344 51.
5. Gupta TK, Tourner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998 28:926 31.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992 339:572 5.
7. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 2005 35:71 9.
8. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006 38:126 36.
9. Bulau P, Zakrzewicz D, Kitowska K, Leiper J, Gunther A, Grimminger F et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol 2007 292:L15 7.
10. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H et al. Sub-pressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res, 2004 27:143 7.
11. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006 62:39 44.
12. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003 23:1455 9.
13. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004 24:1 9.
14. Nijveldt RJ, Teerlink T, Siroen MPC, Van Lambalgen AA, Rauwerda JA, Van Leeuwen PAM. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003 22:17 22.
15. Siroen MPC, Van der Sijp JRM, Teerlink T, Van Schaik C, Nijveldt RJ, Van Leeuwen PAM. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005 41:559 65.
16. Nijveldt RJ, Teerlink T, Van der Hoven B, Siroen MPC, Kuik DJ, Rauweda JA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor in ICU mortality. Clin Nutr 2003 22:23 30.
17. Nijveldt RJ, Teerlink T, Siroen MPC, Van der Hoven B, Prins HA, Wiezer MJ et al. Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy. J Parenter Enteral Nutr 2004 28:382 7.
18. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frölich JC. Elevated plasma and urine levels of ADMA and 15 (S)-8-iso-PGF2α in end-stage liver disease. Hepatology 2003 38:1063 4.
19. Lluch P, Torondel B, Medina P, Segarra G, del Olmo JA, Serra MA et al. Plasma concentration of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004 41:55 9.
20. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, del Olmo JA et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med 2006 231:70 5.
21. Laleman W, Omasta A, Van de Casteele M, Zeegers M, Elst IV, Van Landeghem L et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology 2005 42:1382 90.
22. Intraobserver interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994 20:15 20.
23. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004 39:280 2.
24. Bani-Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995 116:1589 94.
25. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004 42:1377 83.
26. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH. Determination of a reference value for NG,NG-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005 35:622 6.
27. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999 117:1222 8.
28. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995 117:237 8.
29. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000 20:2032 7.
30. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003 42:985 90.
31. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999 99:3092 5.
32. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002 99:13527 32.
33. Batista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997 26:75 80.
34. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humas. Circulation 2004 109:172 7.
35. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005 25:1414 8.
36. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006 37:2024 9.